ORPHA:218
Darier disease
Also known as: Darier-White disease · Keratosis follicularis
Publications
15,063
96.4th percentile
Trials
2
Interventional, condition-specific
Researchers
1,093
Distinct authors in sample
Gene link
ATP2A2
Definitive
Readiness
5/6
Stages with a signal
Clinical definition (Orphanet)
A rare, genetic keratinization disorder which is classically characterized by keratotic papules, acral pits, and acral wart-like lesions that can be associated with a trigger, and may occur anywhere on the body (including mucosal surfaces). Extracutaneous manifestations may include, nail anomalies, blepharitis, dry eye, neuropsychiatric illness and, recurrent parotid gland obstruction and xerostomia.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007417
- MeSH:D007644
- OMIM:124200
- UMLS:C0022595
- NCIT:C84665
Additional Mondo synonyms (3)
Darier's disease · Keratosis Follicularis · keratosis follicularis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
5/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — ATP2A2
- LiteraturePresent
15,063 matched papers (7,907 in last 10 years) Source
- Phenotype characterisedPresent
39 HPO annotations (e.g. Palmar pits; Schizophrenia; Ridged nail) Source
- Animal modelPresent
1 genotype model (Mus musculus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
2 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (ATP2A2).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
39
Associated phenotypes · MONDO:0007417
- Palmar pits
- Schizophrenia
- Ridged nail
- Mild intellectual disability
- Subungual hyperkeratotic fragments
Showing 5 of 39 — open Monarch for the full list.
Animal models (Monarch / Alliance)
1
Model associations linked to this Mondo ID
- Atp2a2tm1Ges/Atp2a2+ [background:] involves: 129X1/SvJ * Black Swiss·MGI:2655642·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
3
Drugs / clinical candidates · MONDO_0007417
- BOTULINUM TOXIN TYPE A·phase 1
- LETIBOTULINUMTOXINA·phase 1
- ONABOTULINUMTOXINA·phase 1
CTD chemicals (MyDisease.info)
3 associated chemicals · 25 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Etretinate · therapeutic
- Fluorouracil · therapeutic
- Lithium · marker/mechanism
Pathways: Calcium signaling pathway; cGMP-PKG signaling pathway; cAMP signaling pathway; Cardiac muscle contraction; Adrenergic signaling in cardiomyocytes; Thyroid hormone signaling pathway; Pancreatic secretion; Alzheimer's disease
Literature
Is anyone studying this?
15,063
15,063 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
15,063 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
7,907 in the last 10 years · medium confidence · 96.4th percentile (publications denominator)
Phrase hits: 3,592 · MeSH hits: 0
Who's working on it?
1,093
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01
- 02Dodiuk-Gad RP5 papers · 2026
Bruce Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel.
Papers in Europe PMC - 03Guenova E5 papers · 2026
Department of Dermatology, University of Lausanne and Faculty of Biology and Medicine, Lausanne, Switzerland.
Papers in Europe PMC - 04Hoetzenecker W5 papers · 2026
Department of Dermatology and Venereology, Kepler University Hospital Linz, Linz, Austria. wolfram.hoetzenecker@kepleruniklinikum.at.
Papers in Europe PMC - 05Kimeswenger S4 papers · 2026
Department of Dermatology and Venereology, Medical Faculty, Johannes Kepler University Linz, Linz, Austria.
Papers in Europe PMC - 06Altrichter S3 papers · 2026
Department of Dermatology and Venereology, Kepler University Hospital Linz, Linz, Austria.
Papers in Europe PMC - 07Burner T3 papers · 2026
Department of Dermatology and Venereology, Medical Faculty, Johannes Kepler University Linz, Linz, Austria.
Papers in Europe PMC - 08Dodiuk-Gad R3 papers · 2026
Department of Dermatology, Emek Medical Center, Afula, Israel.
Papers in Europe PMC - 09Ettinger M3 papers · 2026
Department of Dermatology and Venereology, Kepler University Hospital Linz, Linz, Austria.
Papers in Europe PMC - 10Gudjonsson JE3 papers · 2025
Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; 1 currently recruiting in our sample.
Data as of 11 September 2026 · last trial check 28 July 2026
2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).
medium confidence · 84.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06614777·RECRUITING·Characterization of the Cytokine Profile and the Microbiome in Darier's Disease
Not reviewed·Conditions: Darier Disease·Matched via name phrase
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (1)
- ctis·2024-519201-36-00·Cancelled·Investigator initiated clinical trial of dantrolene as a treatment for Darier disease
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Darier disease — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Darier disease" OR "Darier-White disease" OR "Keratosis follicularis" OR "Darier's disease") OR ("ATP2A2" OR "ATP2A2 syndrome" OR "ATP2A2-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Darier disease" OR "Darier-White disease" OR "Keratosis follicularis" OR "Darier's disease"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T12:56:11.163Z
